Emilija Zimnickaite
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emilija Zimnickaite has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aistė Lisinskaitė
Center of Infectious Diseases, Vilnius University Hospital Santaros Klinikos, Santariskiu Street 14, 08406 Vilnius, Lithuania
1 shared publication - Andrea Dulcey
Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland, unibe.ch
1 shared publication - Andrea Duppenthaler
Division of Pediatric Infectious Disease, Department of Pediatrics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland, unibe.ch
1 shared publication - Birutė Zablockienė
Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-01513 Vilnius, Lithuania
1 shared publication - Christoph Aebi
Division of Paediatric Infectious Diseases, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
1 shared publication Fabienne Stoller
Department of Cardiology, Center for Congenital Heart Disease, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland, unibe.ch
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2026 (1)
Management of Coxiella burnetii Endocarditis in a Child With Congenital Heart Disease
A 6‐year‐old male patient with pulmonary atresia and recent valve replacement with a Melody valve presented with a 6‐week history of fever and cough. He was diagnosed with Coxiella burnetii endocarditis based on a C. burnetii Phase I IgG antibody titre of 1:65,536 and increased metabolic activity surrounding his prosthetic cardiac valve on positron emission tomography scan. Treatment was initiated with doxycycline and hydroxychloroquine. However, despite dose escalation, target plasma concentrations were not achieved. The patient experienced rapid clinical improvement, and serological markers declined gradually. Antimicrobial therapy was discontinued after 40 months, as predefined serological criteria were met, clinical course was favourable, and a follow‐up positron emission tomography scan demonstrated a significant reduction in metabolic activity around the prosthetic valve. Up to 23 months after cessation of therapy, the patient showed no evidence of active C. burnetii endocarditis during follow‐up. The Melody valve maintained its function, and valve replacement was not required. Clinicians should employ an individualised treatment approach to children with C. burnetii endocarditis.
- 1 January 2026
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2026 (1)
Open AccessManagement of Coxiella burnetii Endocarditis in a Child With Congenital Heart Disease
A 6‐year‐old male patient with pulmonary atresia and recent valve replacement with a Melody valve presented with a 6‐week history of fever and cough. He was diagnosed with Coxiella burnetii endocarditis based on a C. burnetii Phase I IgG antibody titre of 1:65,536 and increased metabolic activity surrounding his prosthetic cardiac valve on positron emission tomography scan. Treatment was initiated with doxycycline and hydroxychloroquine. However, despite dose escalation, target plasma concentrations were not achieved. The patient experienced rapid clinical improvement, and serological markers declined gradually. Antimicrobial therapy was discontinued after 40 months, as predefined serological criteria were met, clinical course was favourable, and a follow‐up positron emission tomography scan demonstrated a significant reduction in metabolic activity around the prosthetic valve. Up to 23 months after cessation of therapy, the patient showed no evidence of active C. burnetii endocarditis during follow‐up. The Melody valve maintained its function, and valve replacement was not required. Clinicians should employ an individualised treatment approach to children with C. burnetii endocarditis.
- Open Access
Characteristics of COVID-19 Disease in Renal Transplant Recipients
Background and Objectives: Kidney transplant recipients are at risk of developing more severe forms of COVID-19 infection. The aim of this study was to compare the clinical course of COVID-19 infection among kidney transplant patients and a control group. Materials and Methods: We examined 150 patients hospitalized with COVID-19 infection. Patients were divided into study (kidney transplant recipients, n = 53) and control (without a history of kidney transplantation, n = 97) groups. Demographics, clinical characteristics, treatment data, and clinical outcomes were assessed. Results: The median patient age was 56.0 (46.0–64.0) years, and seventy-seven patients (51.3%) were men. The median Charlson comorbidity index was higher in the study group (3.0 vs. 2.0, p < 0.001). There was a higher incidence of hypoxemia in the control group upon arrival (52.6% vs. 22.6%, p = 0.001) and a higher NEWS index median (2.0 vs. 1.0 points, p = 0.009) and incidence of pneumonia during hospitalization (88.7% vs. 73.6%, p = 0.023). In the study group, there were more cases of mild (26.4% vs. 11.3%, p = 0.023) and critically severe forms of COVID-19 infection (26.4% vs. 3.1%, p < 0.001), kidney failure was more prevalent (34.0% vs. 1.0%, p < 0.001), and a greater number of patients were transferred to the intensive care unit (22.6% vs. 3.1%, p < 0.001) and died (18.9% vs. 1.0%, p < 0.001). Multivariable analysis revealed that treatment in the intensive care unit correlated with a higher mortality rate than transplantation itself (HR = 20.71, 95% CI 2.01–213.33, p = 0.011). Conclusions: The course of the COVID-19 disease in kidney transplant recipients is heterogeneous and can be more severe than in the general population. Even though patients may be hospitalized with fewer symptoms, complications and death are more likely to occur.
Open AccessCharacteristics of COVID-19 Disease in Renal Transplant Recipients
Background and Objectives: Kidney transplant recipients are at risk of developing more severe forms of COVID-19 infection. The aim of this study was to compare the clinical course of COVID-19 infection among kidney transplant patients and a control group. Materials and Methods: We examined 150 patients hospitalized with COVID-19 infection. Patients were divided into study (kidney transplant recipients, n = 53) and control (without a history of kidney transplantation, n = 97) groups. Demographics, clinical characteristics, treatment data, and clinical outcomes were assessed. Results: The median patient age was 56.0 (46.0–64.0) years, and seventy-seven patients (51.3%) were men. The median Charlson comorbidity index was higher in the study group (3.0 vs. 2.0, p < 0.001). There was a higher incidence of hypoxemia in the control group upon arrival (52.6% vs. 22.6%, p = 0.001) and a higher NEWS index median (2.0 vs. 1.0 points, p = 0.009) and incidence of pneumonia during hospitalization (88.7% vs. 73.6%, p = 0.023). In the study group, there were more cases of mild (26.4% vs. 11.3%, p = 0.023) and critically severe forms of COVID-19 infection (26.4% vs. 3.1%, p < 0.001), kidney failure was more prevalent (34.0% vs. 1.0%, p < 0.001), and a greater number of patients were transferred to the intensive care unit (22.6% vs. 3.1%, p < 0.001) and died (18.9% vs. 1.0%, p < 0.001). Multivariable analysis revealed that treatment in the intensive care unit correlated with a higher mortality rate than transplantation itself (HR = 20.71, 95% CI 2.01–213.33, p = 0.011). Conclusions: The course of the COVID-19 disease in kidney transplant recipients is heterogeneous and can be more severe than in the general population. Even though patients may be hospitalized with fewer symptoms, complications and death are more likely to occur.